Omega-3 Supplements for Cardiovascular Disease
(FAS Trial)

Recruiting in Palo Alto (17 mi)

Overseen byMarie-Claude Vohl, Ph.D.

Age: 18 - 65

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Laval University

No Placebo Group

Trial Summary

What is the purpose of this trial?

The main purpose of this study is to examine whether n-3 PUFA-induced changes in metabolic risk factors are influenced by genetic variations within genes acting as fatty acids sensors.

Eligibility Criteria

This trial is for healthy adults aged 18-50 with a BMI of 25-40kg/m2 and normal triglyceride levels. Participants should not smoke, drink alcohol regularly, or have thyroid/metabolic disorders like diabetes or severe dyslipidemia. Pregnant/nursing women and those on certain medications are excluded.

Inclusion Criteria

I am between 18 and 50 years old and healthy.

Plasma triglycerides levels <4.0 mmol/L

My BMI is between 25 and 40.

See 2 more

Exclusion Criteria

I am on medication for high cholesterol, high blood pressure, diabetes, or I take blood thinners or omega-3 supplements.

Body mass index > 40kg/m2

Pregnant or nursing women

See 1 more

Treatment Details

Interventions

n-3 PUFA Supplementation (Omega-3 Fatty Acids)

Trial OverviewThe study is testing the effects of n-3 PUFA (Omega-3 fatty acid) supplements on metabolic risk factors related to cardiovascular disease, considering genetic variations that might affect how individuals respond to these fats.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: capsules omega-3Experimental Treatment1 Intervention

Omega-3 supplementation (3g EPA+DHA/d)